康莱特注射液联合胸腔灌注化疗对晚期非小细胞肺癌恶性胸水患者的临床疗效  

Clinical effect of Kanglaite injection combined with intrapleural infusion chemotherapy in the treatment of patients with malignant pleural effusion of advanced non-small cell lung cancer

作　　者：侯强[1] 许崇文[1] 董南 任宏[1] 

机构地区：[1]西安交通大学医学院第一附属医院,陕西西安710061 [2]西安521医院,陕西西安710065

出　　处：《现代肿瘤医学》2015年第23期3417-3420,共4页Journal of Modern Oncology

摘　　要：目的:观察康莱特注射液对晚期非小细胞肺癌恶性胸水患者的临床疗效。方法:将88例晚期非小细胞肺癌恶性胸水患者随机分为三组,实验组(胸腔灌注化疗+康莱特注射液)30例;阳性对照组(胸腔灌注化疗+参芪扶正注射液)29例和对照组(单纯胸腔灌注化疗)29例。对三组患者治疗前后的外周血象(白细胞、血红蛋白、血小板),T细胞亚群分类(CD4、CD8、CD4/CD8),免疫球蛋白(Ig A、Ig G、Ig M),近期临床疗效以及不良反应进行比较。结果:治疗前,三组之间外周血象及T淋巴细胞的免疫活性无统计学差异(P>0.05);治疗后,实验组T淋巴细胞免疫活性高于另外两组(P<0.05),同时阳性对照组T淋巴细胞的免疫活性要高于对照组(P<0.05)。化疗后,对照组免疫球蛋白Ig G、Ig A及Ig M较化疗前均降低(P<0.05);实验组免疫球蛋白Ig G和Ig M均明显高于阳性对照组和对照组(P<0.05)。实验组近期临床疗效明显高于阳性对照组和对照组(P<0.05);阳性对照组的总有效率也明显高于对照组(P<0.05)。实验组和阳性对照组的粒细胞集落刺激因子使用量明显低于对照组(P<0.05),三组间出现的其他不良反应无显著统计学差异(P>0.05)。结论:康莱特注射液联合胸腔灌注化疗治疗晚期非小细胞肺癌恶性胸水的患者,可以保护机体的细胞免疫和体液免疫功能,提高临床疗效,减轻患者的骨髓抑制不良反应,是配合胸腔灌注化疗的一种较理想的辅助治疗药物。Objective： To explore the clinical effect of Kanglaite injection in the treatment of patients with malignant pleural effusion of advanced non-small cell lung cancer. Methods： All 88 patients with malignant pleural effusion of advanced non-small cell lung cancer were randomly divided into 3 groups,the treatment group（ 30 cases）was treated with Kanglaite injection and intrapleural infusion chemotherapy,the positive control group（ 29 cases） was treated with Shenqi Fuzheng injection and intrapleural infusion chemotherapy,and the control group（ 29 cases） was treated with intrapleural infusion chemotherapy alone. To observe and compare the change of peripheral hemogram（ white blood cells,hemoglobin,platelet）,T cell subsets classification（ CD4,CD8 and CD4 /CD8） and immunoglobulin（ Ig A,Ig G,Ig M） before and after treatment. Results： Before treatment,there was no significant differences of peripheral hemogram and immune activity of T lymphocyte among the 3 groups（ P〉0. 05）. After treatment,immune activity of T lymphocyte in treatment group was higher than the other 2 groups（ P〈0. 05）,and immune activity of T lymphocyte in positive control group was higher than that in control group（ P〈0. 05）. The immunoglobulin（ Ig A,Ig G,Ig M） of the control group decreased after treatment（ P〈0. 05）. After treatment Ig G and Ig M in the treatment group were higher than that in positive control group and control group（ P〈0. 05）. The short-term clinical effect oftreatment group was better than that in the other groups,and the short-term clinical effect of positive control group was better than that in control group（ P〈0. 05）. The usage of G-CSF in treatment group and positive group was less than that in control group（ P〈0. 05）,whereas there was no significant difference on other toxic and adverse reaction among three groups（ P〉0. 05）. Conclusion： Treatment with Kanglaite injection combined with intrapleural infusion chemotherapy enhances cellular and humor

关 键 词：肺癌 胸腔灌注化疗 康莱特注射液 临床疗效 

分 类 号：R730.53[医药卫生—肿瘤] R734.2[医药卫生—临床医学]